Draft:Terry Pirovolakis

Terry Pirovolakis (born 1979) is a Canadian technologist and biotech leader focused on developing treatments for ultra-rare disorders. He has spent much of his career in IT, building call centers and CRM systems for Fortune 500 companies worldwide. In 2019, his youngest son, Michael, was diagnosed with SPG50, an ultra-rare disease. In response, Terry and his family founded CureSPG50 to raise funds for research and treatment for this condition, which affects fewer than 200 children globally. Within three years, they raised $4.5 million and developed a treatment for Michael and others with SPG50. Following this achievement, Terry founded Elpida Therapeutics SPC, a biotech company run as a non-profit, dedicated to providing gene therapies to children in need worldwide.